Central Trust Company’s Ultragenyx Pharmaceutical RARE Stock Holding History

Central Trust Company’s Portfolio RARE Stock Details RARE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-24	Closed	-$873	–	1497
2025 Q2	$873	Hold	24	–	–	﹤0.01%	1380
2025 Q1	$870	Hold	24	–	–	﹤0.01%	1387
2024 Q4	$1.01K	Hold	24	–	–	﹤0.01%	1381
2024 Q3	$1.33K	Hold	24	–	–	﹤0.01%	1292
2024 Q2	$987	Hold	24	–	–	﹤0.01%	1336
2024 Q1	$1.12K	Hold	24	–	–	﹤0.01%	1312
2023 Q4	$1.15K	Hold	24	–	–	﹤0.01%	1321
2023 Q3	$856	Buy	+24	New	+$951	﹤0.01%	1319

Other funds holding RARE

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Central Trust Company's RARE Position: Q3 2025 in Review

Central Trust Company sold out of Ultragenyx Pharmaceutical (RARE) in Q3 2025, closing a stake of 24 shares — an estimated $873 sold.

Central Trust Company first reported a position in RARE in Q3 2023 and held it in 8 quarters. The position peaked at $1.33K in Q3 2024. 302 funds tracked by Wall St. Rank hold RARE as of Q3 2025.

Central Trust Company reported no remaining Ultragenyx Pharmaceutical position as of Q3 2025 after selling out during the quarter.
Central Trust Company sold 24 Ultragenyx Pharmaceutical shares in Q3 2025, an estimated $873.
Central Trust Company first reported a position in Ultragenyx Pharmaceutical in Q3 2023 and held it in 8 quarters.
Central Trust Company's Ultragenyx Pharmaceutical position peaked at $1.33K in Q3 2024.
302 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q3 2025.

Based on Central Trust Company's 13F filing for Q3 2025, filed 6 Nov 2025.